Sterneck Capital Management, LLC Cellectar Biosciences, Inc. Transaction History

Sterneck Capital Management, LLC

  • $179 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$3.5 - $6.9 $105,000 - $207,000
-30,000 Closed
0 $0
Q2 2021

Jul 30, 2021
BUY
$11.8 - $18.2 $354,000 - $546,000
30,000 New
30,000 $34,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.59M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Sterneck Capital Management, LLC Portfolio

Follow Sterneck Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sterneck Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sterneck Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email